BPC-157 and the Eye: What the Published Research Actually Says

Published August 22, 2026 · Artemis Labs

BPC-157 eye research — The published record on BPC-157 and the eye is small. It rests mainly on one 2023 review by Sikiric and colleagues, which gathered animal studies of glaucoma and other eye conditions. In those preclinical models, researchers reported changes in growth-factor signals — VEGF, EGF, and HGF — that the body uses during tissue repair. No human trial has tested BPC-157 for any eye condition, and no Phase II or Phase III human efficacy trial exists for any use of the compound. The eye is one of the least-studied areas in the BPC-157 literature, and any page that suggests otherwise is overselling it.

Key findings

• A 2023 review by Sikiric and colleagues (DOI: 10.3390/ph16071052) is the anchor for this research area. It summarized animal models of glaucoma and other eye conditions — it did not report any human data.
• In ocular preclinical models covered by that review, researchers reported increased levels of three growth factors: VEGF, EGF, and HGF. These are signaling proteins the body uses to grow new blood vessels and repair tissue.
• The same multi-growth-factor pattern was reported in unrelated animal models, including an alkali-burn wound model (Huang 2015, DOI: 10.2147/DDDT.S82030) and a fistula-repair model in rats (Baric 2016, DOI: 10.1016/j.lfs.2016.02.029).
• There is no published human efficacy trial of BPC-157 for the eye or for anything else. Every statement about what the compound might do in eye tissue is an extrapolation from animal work.

What is BPC-157?

BPC-157 is a peptide — a short chain of amino acids, the building blocks of proteins. It is 15 amino acids long, and its sequence is a partial copy of a protein found in human gastric juice, the acidic fluid in the stomach. That origin gives it an unusual trait for a small peptide: published studies report it stays intact in human gastric juice for more than 24 hours, when most unmodified peptides break down quickly.

Most research on the compound has nothing to do with the eye. The bulk of the animal literature looks at how tendons, ligaments, muscle, and the gut lining heal, along with how new blood vessels form at injury sites. We cover the largest of those areas in our page on BPC-157 wound research. The BPC-157 research peptide sold by Artemis Labs is supplied for laboratory work in these kinds of models, not for use in people.

What is glaucoma?

Glaucoma is not one disease. It is a group of eye conditions in which the optic nerve — the cable of nerve fibers that carries images from the back of the eye to the brain — becomes damaged. The damage is often connected to raised pressure from the fluid inside the eye. Sight lost this way does not come back, which is why the condition matters so much and why researchers build animal models of it.

An animal model means scientists recreate a version of the condition in a lab animal, usually a rat, so they can test whether a compound changes how the disease behaves. A result in a rat model is a starting point for research. It is not evidence that the same thing happens in a human eye.

What does the published eye research cover?

The backbone of this research area is a single paper: a 2023 review by Sikiric and colleagues (DOI: 10.3390/ph16071052). A review is a paper that collects and summarizes earlier studies rather than running a new experiment. This one gathered the animal work on BPC-157 in glaucoma models and other eye conditions and laid out what those studies reported.

That is worth sitting with for a moment. For tendon or gut research, the BPC-157 literature has multiple primary studies plus reviews built on top of them. For the eye, one review carries the area. We think stating that plainly is more useful to a researcher than dressing a thin evidence base up as a thick one. If you want the broader picture of where the whole BPC-157 record stood going into 2026 — which model systems exist, and where the first human-tissue data appeared — see our summary of the 2026 preclinical foundation and human-tissue evidence.

How might BPC-157 act in eye tissue?

The mechanism reported in ocular models involves growth factors. A growth factor is a signaling protein — a chemical message that tells nearby cells to grow, divide, or start repairs. Three come up in this part of the literature:

• VEGF (vascular endothelial growth factor), the body’s main signal for growing new blood vessels;
• EGF (epidermal growth factor), a signal that pushes surface-lining cells to multiply and close over damage;
• HGF (hepatocyte growth factor), first identified in liver cells and involved in tissue repair more broadly.

In the ocular animal models reviewed by Sikiric 2023, researchers reported that BPC-157 raised levels of all three. The same pattern was reported in animal models far from the eye: an alkali-burn wound model (Huang 2015) and a rectovaginal-fistula repair model in rats (Baric 2016). That consistency across very different tissues is why researchers describe BPC-157 as having a growth-factor-pathway profile.

Two caveats belong right next to that. BPC-157 has no single identified receptor — no one docking site on cells that fully explains its reported effects — and no standard lab assay defines what a positive response looks like. And across the animal literature, the size of reported effects varies a great deal with the model, the dose used in the study, and the species. A raised growth-factor reading in a rat eye model is an observation, not a mechanism settled to the standard pharmacology usually demands.

What the research does not show

This section matters more on this page than on most, because the evidence base behind it is one of the smallest in the BPC-157 literature.

No human eye data exists. No clinical trial has tested BPC-157 in the human eye, for glaucoma or for any other eye condition. The Sikiric 2023 review summarizes animal models only.

No human efficacy trial exists for any use. BPC-157 has never completed a Phase II or Phase III human trial — the studies that test whether a compound actually works in people — for any condition anywhere in the body. Every efficacy statement in circulation is extrapolated from animal or tissue studies.

One review is not a body of evidence. A review can only be as strong as the studies it collects, and it cannot turn animal findings into human ones. Nothing here shows any effect of BPC-157 on glaucoma or any other eye condition in people.

The mechanism is open. With no defined receptor and effect sizes that shift between models, the growth-factor findings describe what was observed, not why, and not what would happen in a human eye.

Frequently asked questions

Has BPC-157 been tested in people for eye conditions?

No. The published eye research consists of animal models, gathered in the 2023 Sikiric review. There is no human eye trial of any kind.

Does the 2023 review show that BPC-157 helps glaucoma?

No. It shows that in rat and other animal models of glaucoma and eye injury, researchers reported effects linked to growth-factor signaling. Animal findings regularly fail to repeat in humans, which is exactly why efficacy trials exist — and none has been run.

Why do researchers look at growth factors in the eye at all?

Growth factors like VEGF, EGF, and HGF are the body’s repair messengers: they direct new blood-vessel growth and tissue rebuilding. Because ocular models reported BPC-157 raising all three, the compound became a candidate for further study in eye-injury models.

Is the eye a major focus of BPC-157 research?

No. Tendon, ligament, muscle, gut, and blood-vessel models make up most of the literature. The eye is one of the least-studied areas, anchored by a single review.

References

1. Sikiric P, et al. (2023). Review of BPC-157 in glaucoma and other ocular-condition animal models. Pharmaceuticals. DOI: 10.3390/ph16071052
2. Huang T, et al. (2015). Alkali-burn wound healing in vivo; proliferation, migration, and angiogenesis readouts in vitro. Drug Design, Development and Therapy. DOI: 10.2147/DDDT.S82030
3. Baric M, et al. (2016). Rectovaginal fistula repair in rats. Life Sciences. DOI: 10.1016/j.lfs.2016.02.029

Methodology: This page draws solely on the Artemis Labs BPC-157 verified research record (citations verified May 2026; sheet compiled August 22, 2026); last reviewed August 22, 2026.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.